The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, features a selection of new medicines undergoing clinical evaluation or in pre-registration that may gain market authorization in Canada in the future. There were 10,501 drugs in the pipeline as of August 2025. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
Minister of Health Marjorie Michel (Papineau, Que.) tabled the 2024 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons. The 2024 Annual Report reviews trends in the prices and sales of patented medicines in Canada. Sales of patented medicines in 2024 were $22.1 billion and accounted … Read more
The latest edition of the Patented Medicine Prices Review Board (PMPRB) CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4 per cent in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22. Drugs costing over $10,000 annually accounted for over one third of total drug costs for the public drug … Read more